Liao Geraldine J, Clark Amy S, Schubert Erin K, Mankoff David A
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and.
J Nucl Med. 2016 Aug;57(8):1269-75. doi: 10.2967/jnumed.116.175596. Epub 2016 Jun 15.
Estrogen receptor (ER) expression in breast cancer is associated with a more favorable prognosis and is necessary for a response to endocrine therapies. Traditionally, ER expression is assessed by in vitro assays on biopsied tumor tissue. However, recent advances have allowed in vivo evaluation of ER expression with (18)F-fluoroestradiol ((18)F-FES) PET. Clinical studies have demonstrated the use of (18)F-FES PET as a method for quantifying in vivo ER expression and have explored its potential as a predictive assay and method of assessing in vivo pharmacodynamic response to endocrine therapy. This review outlines the biology and pharmacokinetics of (18)F-FES, highlights the current experience with (18)F-FES in patient studies on breast cancer and other diseases, and discusses potential clinical applications and the possible future clinical use of (18)F-FES PET.
雌激素受体（ER）在乳腺癌中的表达与更良好的预后相关，并且是对内分泌治疗产生反应所必需的。传统上，ER表达是通过对活检肿瘤组织进行体外检测来评估的。然而，最近的进展使得能够利用（18）F-氟雌二醇（（18）F-FES）PET对ER表达进行体内评估。临床研究已经证明使用（18）F-FES PET作为定量体内ER表达的一种方法，并探索了其作为预测性检测方法以及评估体内对内分泌治疗的药效学反应的潜力。这篇综述概述了（18）F-FES的生物学和药代动力学，强调了目前在乳腺癌及其他疾病患者研究中使用（18）F-FES的经验，并讨论了（18）F-FES PET的潜在临床应用及未来可能的临床用途。
